Millennium Identifies 18 Drug Targets for Bayer

Oct 07, 1999

Premium

CAMBRIDGE, Mass.--Millennium Pharmaceuticals and Bayer announced that they have identified 18 novel drug targets and moved four of them into high-throughput screening in less than eight months. In the collaboration, which is taking a production-oriented approach based on genomics research to move compounds toward clinical trials, targets were identified and validated by Millennium and are being screened by Bayer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Drive Away the Flies

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

Fewer Transfusions Needed

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

This Week in Nature

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Alteration Here and There to Win

Futurism writes that gene doping could be the next generation of cheating in sports.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu